GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Other Long-Term Liabilities

Diamyd Medical AB (OSTO:DMYD B) Other Long-Term Liabilities : kr45.55 Mil (As of May. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Other Long-Term Liabilities?

Diamyd Medical AB's other long-term liabilities for the quarter that ended in May. 2025 was kr45.55 Mil.

Diamyd Medical AB's quarterly other long-term liabilities declined from Nov. 2024 (kr43.62 Mil) to Feb. 2025 (kr42.99 Mil) but then increased from Feb. 2025 (kr42.99 Mil) to May. 2025 (kr45.55 Mil).

Diamyd Medical AB's annual other long-term liabilities declined from Aug. 2022 (kr0.00 Mil) to Aug. 2023 (kr0.00 Mil) but then increased from Aug. 2023 (kr0.00 Mil) to Aug. 2024 (kr0.00 Mil).

Diamyd Medical AB Other Long-Term Liabilities Historical Data

The historical data trend for Diamyd Medical AB's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Other Long-Term Liabilities Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Diamyd Medical AB Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.57 - 43.62 42.99 45.55

Diamyd Medical AB Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Diamyd Medical AB Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Other Long-Term Liabilities
Comparable Companies
OSTO:SANION OSTO:EGTX OSTO:XSPRAY OSTO:GENO OSTO:HNSA OSTO:SYNACT OSTO:VICO XSAT:HAMLET B OSTO:IBT B OSTO:FLUO VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
DYMDF:USA
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Website
https://www.diamyd.com
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines